Benzinga··Soligenix, Inc.Soligenix's HyBryte Outperforms Valchlor in Cutaneous Lymphoma Study
Soligenix's HyBryte demonstrated superior efficacy versus Valchlor in treating cutaneous T-cell lymphoma, with 60% versus 20% success rates at 12 weeks, backed by $2.6M FDA grant.
SNGXFDA approvalclinical trial